Você está deixando o Portal Médico GSK

Você está prestes a deixar o site da GSK. Ao clicar neste link, você será direcionado a um site que não pertence ou é controlado pela GSK. Portanto, a GSK não é responsável por demais conteúdos presentes neste site.

Continuar

Voltar

Guideline de tratamento da asma grave (ERS/ATS)

Dr. Roberto Stirbulov (CRM-SP 38.357) define os diferentes tipos de asma grave e a melhor abordagem terapêutica para cada tipo.

  • 1. GLOBAL INITIATIVE FOR ASTHMA. Global strategy for asthma management and prevention. 2017. Disponível em: http://ginasthma.org/2017-gina-report-global-strategy-for-asthma-management-and-prevention/. Acesso em: 25 jan. 2018.

    2. CHUNG, KF. et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J, 43(2):343-73, 2014.

    3. KUPCZYK, M. et al. Frequent exacerbator-a distinct phenotype of severe asthma. Clin Exp Allergy, 44(2):212-21, 2014.

    4. MCDONALD, VM. et al. Severe asthma: Current management, targeted therapies and future directions-A roundtable report. Respirology, 22(1):53-60, 2017.

    5. BARNES, PJ. et al. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol, 131(3):636-45, 2013.

    6. KOCZULLA, AR. et al. New concepts in asthma: clinical phenotypes and pathophysiological mechanisms. Drug Discovery Today, 22(2):388-96, 2017.

    7. WENZEL, S. Phenotypes & Endotypes: Emerging concepts on asthma heterogeneity. In: AKDIS, CA. et al. Global atlas of asthma.

    8. MIRANDA, C. et al. Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol, 113(1):101-8, 2004.

    9. HALDAR, P. et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med, 178(3):218-24, 2008.

    10. PAVORD, ID. et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicenter, double-blind, placebo-controlled trial. Lancet, 380(9842): 651-9, 2012.